Skip directly to content

Publications 2015

HCV Fact Sheets in English and en Español
December 14, 2015 – This set of fact sheets include information on adherence to treatment, HCV diagnostics, and currently approved treatments (Sovaldi, Olysio, Viekira Pak and Technivie, Harvoni, Daklinza, and ribavirin).

2015 TAGupdate
December 13, 2015 

  • Letter from Kenyon Farrow, TAG's U.S. & Global Health Policy Director
  • Message from Board President Barbara Hughes
  • Ending the Epidemic Update
  • HCV Report from the Front

An Activist’s Guide to Regulatory Issues: Ensuring Fair Evaluation of and Access to Tuberculosis Treatment
December 2015 – This guide explains different regulatory processes and terms and offers examples of how to use a variety of regulatory mechanisms to improve access to treatment. The guide also encourages activists to advocate for effective, efficient, transparent regulatory systems.

2015 Report on Tuberculosis Research Funding Trends, 2005–2014: A Decade of Data
November 30, 2015 – Ten years of data collected by Treatment Action Group (TAG) show that funding shortfalls for TB research and development (R&D) are serious and chronic.

2015 Pipeline Report
July 17, 2015 – HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

TAGline Fall 2015
October 2015

  • In Defense of Stringency
    In response to growing public concern with health risks posed by approved drugs, a 2006 landmark report by the Institute of Medicine (IOM) argued that the U.S. Food and Drug Administration (FDA) lacks the unambiguous authority necessary to ensure the safety and efficacy of the country’s medicinal products. The IOM emphatically recommended that Congress enact any legislation necessary to buttress the agency’s enforcement powers so that it may apply the strengths of the pre-approval process, including stringent data review, to postapproval monitoring and regulation. Nine years later, Congress and federal courts have followed a markedly different course. Instead of ensuring agency leadership and resources, they have continued assaults on the FDA’s regulatory powers—eroding not only its postapproval oversight, but also the safety and efficacy requirements for its approval of drugs and medical devices.
  • The 21st Century Cures Act’s “Pathway to Crisis” in Drug Safety
    Federal legislation promises a substantial increase in NIH funding—at the expense of a significantly weakened FDA
  • The FDA’s Concession Conundrum
    Can regulatory incentives promote responsible TB drug development?
  • The Challenge of Defining HIV Remission
    Supportive regulatory guidance for cure research requires a clear understanding of all possible outcomes, including remission
  • Improving Regulatory Systems to Address Global TB Drug Access Failures
    Worldwide inefficiencies in drug approval processes are proving disastrous for people living with TB and other diseases
  • PrEP: The Pathway to Global Access
    Regulatory filing and review delays keep Truvada as pre-exposure prophylaxis out of reach of those who need it most

Toward Comprehensive HIV Prevention Service Delivery in the United States: An Action Plan
June 24, 2015 – An objective of the National HIV/AIDS Strategy (NHAS), released by the White House in July 2010, is to lower the annual number of new infections in the United States by 25 percent by the end of 2015. Yet it is unclear if we will succeed in meeting this arguably unambitious target: 36,400 estimated new infections in 2015, compared with the 48,600 new infections estimated for the baseline year of 2006.

Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries
February 2, 2015 – This report presents a number of key strategies through real-world case studies and shows how strategies used to combat the AIDS epidemic can be—and have been—adapted to increase HCV treatment access. These strategies are introduced in three sections: Laying the groundwork through community organizing; overcoming the cost barriers to HCV treatment access; and collaborating with researchers to build your case for HCV treatment access.